DOI: 10.5281/zenodo.5919956
title: TomoBreast randomized clinical trial's lung-heart outcomes and mortality through the 2020 COVID-19 pandemic: data and software

description: Dataset and R script to reproduce the analyses of the manuscript:

Vinh-Hung V, Gorobets O, Adriaenssens N, Van Parijs H, Storme G, Verellen D, Nguyen NP, Magne N, De Ridder M.

Lung-heart outcomes and mortality through the 2020 COVID-19 pandemic in a prospective cohort of breast cancer radiotherapy patients.

Cancers 2022; 14(24):6241. https:// doi.org/10.3390/cancers14246241

https://www.mdpi.com/2072-6694/14/24/6241

PubMed: PMID: 36551726

PMCID: PMC9777311

Info on the variables in file "aelq6_public.R"

reproduced in "aelq_2_3_readme.txt":

"aelq2_base2.txt" = baseline characteristics.

"aelq3.txt" = longitudinal maesurements.

Variables in "aelq2_base2.txt":

"aelq2_base2.txt" = baseline characteristics. # Age at randomization, years. # RTdose: cf TomoBreast papers. # 51 Gy = hypofractionated, simultaneous integrated boost# 42 Gy = hypofractionated, no boost, mastectomy cases only# 50 Gy = conventional, no boost, mastectomy cases only# 66 Gy = conventional, sequential boost# Weight kg, Height cm, # Detection 1=found by screening (senology follow-up/controle)#     2=found by symptoms (pain, palpable)#     9=unknown# Smoker     0= Not smoker#     1= Smoker#     2=ex-smoker# Mastectomy (and other binary coded) 1= yes# chemosched 0=none#     1= planned after RT (sequential)#     2= prior to RT and is finished (sequential)#     3= chemo is on-going or is planned to start with RT (concomitant)# hormonetherapy     0=no#     1=tamoxifen (nolvadex)#     2=Femara (Letrozole)#     3=zoladex#     4=tamoxifen + zoladex# Laterality 1,=Right, 2=Left, 3=Bilateral# LengthFU: length of follow-up, days from randomization

"aelq3.txt" = longitudinal maesurements.# "Nr" = Case ID# "Time" in days from origin (origin =date of randomization), # if negative =before randomization#    "KPS"       "Weight"    # "Died"      "LocalRec"  "Metast"    "NewPrim"   = binary code, 0=no, 1=yes# "fAEBreast" "fAEHeart"  "fAELung"   "fAEOther" # fAE = freedom from breast, heart, lung, other adverse event score# "LVEF2" = ejection fraction, %# "MacIver" = estimated cardiac strain

# the following are pulmonary function tests, untransformed units# "FVC", "FEV1", "PEF", "VC", "TLC", "RV", "FRC", "Raw", "sRaw", "DLCO",# "VA", "PF"

# "fDY", "fFA", "fPA" = freedom from dyspnea, from fatigue, from pain# range 0 to 100 (best)# see papers:

# Van Parijs, H.; Vinh-Hung, V.; Fontaine, C.; Storme, G.; Verschraegen, C.;# Nguyen, D.M.; Adriaenssens, N.; Nguyen, N.P.; Gorobets, O.; De Ridder, M.# Cardiopulmonary-related patient-reported outcomes in a randomized clinical# trial of radiation therapy for breast cancer. BMC Cancer 2021, 21, 1177,# doi:10.1186/s12885-021-08916-z.

# preprint:# Van Parijs, H.; Cecilia-Joseph, E.; Gorobets, O.; Storme, G.; # Adriaenssens, N.; Heyndrickx, B.; Verschraegen, C.; Nguyen, N.P.;# De Ridder, M.; Vinh-Hung, V. Lung-heart toxicity in a randomized # clinical trial of hypofractionated image guided radiation therapy for# breast cancer. Preprints 2022, 202212, 0214.# https://doi.org/10.20944/preprints202212.0214.v1

# # "Year" = year of the observation# example: randomized 1/1/2011, measurement done 1/31/2011, time = 30 days,# Year =2011# 
description: Lung-heart toxicity in a randomized clinical trial of hypofractionated image guided radiation therapy for breast cancer.

Van Parijs H, Cecilia-Joseph E, Gorobets O, Storme G, Adriaenssens N, Heyndrickx B, Verschraegen C, Nguyen NP, De Ridder M, Vinh-Hung V.Front Oncol. 2023 Nov 20;13:1211544. doi: 10.3389/fonc.2023.1211544. eCollection 2023.PMID: 38053657 

 

https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1211544/full